Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Vöslau – page 23

865 clinical trials in Bad Vöslau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Vöslau at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Bad Vöslau

Open in trial search

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Study on the Safety and Tolerability of Treprostinil Sodium for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Treprostinil Sodium
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Miltenyi Biomedicine GmbH

Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Transthera Sciences (Nanjing) Inc.

Study of Cytarabine, Daunorubicin, and Clofarabine for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Clofarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Exelixis Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Vöslau

What the registry says about research in the country

01 Neuropathic Pain Studies

Investigating new treatment approaches for patients with diabetic polyneuropathy, focusing on innovative pain management solutions that could improve quality of life for those affected by chronic neuropathic conditions.

  • Diabetic Neuropathy Management
  • Chronic Pain Treatment
  • Add-on Therapy Evaluation

Research aims to enhance current treatment protocols for diabetes-related nerve pain.

02 Trauma-Related Neuropathy

Evaluating therapeutic options for patients experiencing post-operative and traumatic peripheral neuropathy, with a focus on developing effective pain management strategies for those affected by surgery or injury-related nerve damage.

  • Post-surgical Pain Management
  • Trauma-induced Neuropathy
  • Peripheral Nerve Pain

Studies explore innovative approaches to managing chronic pain resulting from surgical procedures and trauma.

03 Central Neuropathy Research

Examining treatment efficacy for central neuropathy of various origins, investigating novel therapeutic approaches for managing chronic pain associated with central nervous system conditions.

  • Central Nervous System Pain
  • Neurological Pain Management
  • Pain Relief Strategies

This research explores comprehensive treatment options for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigating innovative therapies for patients suffering from chronic back pain, focusing on developing effective add-on treatments to enhance current pain management approaches.

  • Back Pain Management
  • Long-term Pain Relief
  • Therapeutic Advancement

Studies aim to improve treatment outcomes for individuals with persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.